Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes

Diabetes Research and Clinical Practice
José Antonio Gimeno-OrnaFrancisco J Castro-Alonso

Abstract

We attempted to assess whether microalbuminuria conferred the same cardiovascular risk as overt CVD in type 2 diabetic patients. A prospective cohort study including 436 type 2 diabetic patients (64.8+/-9.2 years old) without proteinuria, with follow-up until any cardiovascular event occurred, was performed. Patients were classified into four groups: group 0, non baseline CVD and normoalbuminuria; group 1, non baseline CVD and microalbuminuria; group 2, baseline CVD and normoalbuminuria; group 3, baseline CVD and microalbuminuria. Cox's multivariate regression models were used to assess the risk ratio (RR) associated with each variable. The median follow-up time was 7.6 years. Incidence rates of cardiovascular events per 1000 patient-years increased from groups 0 to 3 (23.8, 63.4, 74.1, 85.6; p<0.0001). Multivariate RR for incident CVD in groups 1, 2 and 3 in relation to group 0 were 2.8 (95% confidence interval (CI) 1.7-4.6; p<0.0001), 2.7 (95% CI 1.6-4.6; p<0.0001) and 2.9 (95% CI 1.6-5.4; p=0.001), respectively. No significant differences were seen between groups 1 and 2. We suggest that patients with microalbuminuria are at very high vascular risk and should share the same objectives of a vascular risk-factor control as pat...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Nov 29, 2001·Clinical Science·R J StevensUNKNOWN United Kingdom Prospective Diabetes Study (UKPDS) Group
Jul 10, 2002·Stroke; a Journal of Cerebral Circulation·Viti KothariRudy R Holman
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Dec 21, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·J A Gimeno-OrnaM A Sancho-Serrano
Dec 25, 2004·Diabetes Care·UNKNOWN American Diabetes Association
Apr 12, 2005·Current Opinion in Nephrology and Hypertension·Matthew F YuyunNicholas J Wareham

❮ Previous
Next ❯

Citations

Feb 15, 2011·International Journal of Clinical Practice·M Mata-CasesM I Fernández-Sanmartín
Feb 20, 2007·The American Journal of Cardiology·LaDale St Clair, Christie M Ballantyne
Jun 2, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·C L BlacklockA J Farmer
Mar 12, 2010·Diabetes/metabolism Research and Reviews·Agnès MathesonBradley J Walsh
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.